#ISTH2022

SUPPORTED SYMPOSIA & PRESENTATION THEATERS
ISTH 2022 Supported Symposia & Presentation Theaters
(as of7/10/22)
The following companies will organize supported symposia and/or presentation theater sessions at the ISTH 2022 Congress in London, showcasing the latest scientific, diagnostic and therapeutic advances in thrombosis and hemostasis.
See below for session titles.
Live Supported Symposia and Presentation Theaters
Saturday, July 9, 11:30 – 12:45 Supported Symposia
-
AAV Gene Therapies: Learnings From Clinical Trials to Inform Real World Discussions (BioMarin Pharmaceutical Inc.) ICC Capital Suites 7&12
-
Anticoagulant Advancements for VTE in All Ages and NVAF in Adult Patients (Boehringer Ingelheim) ICC Capital Suites 10&11
-
Living with ITP: Thrombotic Risk and Patient’s Perspective (GRIFOLS) ICC Capital Suite 1
-
A Key Factor: Aiming for All-Round Bleed Protection in Haemophilia A (Octapharma AG) ICC Capital Suites 14-16
-
Shining a Light on Severe Congenital Protein C Deficiency (SCPCD) (Takeda Pharmaceutical Company Limited) ICC Capital Suites 8&9
Sunday, July 10, 07:00 – 07:45 Supported Symposium
-
Navigating the Joint Health Journey for Patients With Hemophilia: How Can You Make A Lasting Impact? (MedScape/ISTH/Takeda Pharmaceuticals U.S.A, Inc.) ICC Capital Suite 1
Sunday, July 10, 12:15 – 13:00 Presentation Theaters
-
Achieving Balance with Prophylaxis in Hereditary Factor X Deficiency – Treatment Across the Ages (Bio Products Laboratory Ltd.) Presentation Theater 3
-
MRX PT DOAC – a New Way to Measure the Effect of DOACs (Nordic Biomarker) Presentation Theater 4
-
Rapid Reversal of DOACs: Current and Future Perspectives (Norgine) Presentation Theater 2
-
Managing the Challenges of IVDR Transition Together (Siemens Healthineers) Presentation Theater 1
Sunday, July 10, 13:15 – 14:30 Supported Symposia
-
Make the Right Call: Protecting Vulnerable Patients With Venous Thrombosis (Bayer AG) ICC Capital Suites 2-4
-
Advancing Care for Haemophilia: How Do We Keep Up With the Times? (CSL Behring) ICC Capital Suites 7&12
-
Evidence-Based Responses to Key Clinical Questions Relating to Hemophilia A Management (F. Hoffmann-La Roche Ltd) ICC Capital Suites 10&11
-
COVID-19 Coagulopathy and Long COVID: Haemostatic Changes and Implications for Diagnosis and Treatment (Haemonetics Corporation) ICC Capital Suites 17
-
Health Equity for Haemophilia Patients with Inhibitors: Can We Do More? (LFB) ICC Capital Suite 1
-
Mind the Gap: The Journey to Address Unmet Needs Across all Haemophilia Indications (Novo Nordisk) ICC Capital Suites 14-16
-
Immune Thrombocytopenia: Disease Burden and Treatment Challenges in the COVID-19 Era (Sanofi) ICC Capital Suites 8&9
Monday, July 11, 07:00 – 07:45 Supported Symposium
-
Management of Thrombosis in High-Risk Patients: Focus on Cancer-Associated Thrombosis (CAT) (Anthos Therapeutics) ICC Capital Suite 17
Monday, July 11, 07:00 – 07:45 Presentation Theater
-
Implementing a Multimodal Approach to VTE Prevention Today (Cardinal Health) ICC Capital Suite 1
Monday, July 11, 12:15 – 13:00 Presentation Theaters
-
Advances in von Willebrand Disease (vWD): A View From the Clinic (CSL Behring) Presentation Theater 3
-
Driving Change: Improving Diagnosis of Heavy Menstrual Bleeding and Bleeding Disorders in Women and Girls (Novo Nordisk Healthcare AG) Presentation Theater 4
-
Lupus Anticoagulant Diagnostics: Why you Need More Snakes (Technoclone) Presentation Theater 1
-
ADAMTS13 and von Willebrand Factor Axis (Werfen) Presentation Theater 2
Monday, July 11, 13:15 – 14:30 Supported Symposia
-
Roundtable Discussion: Clinical Challenges in Patients with Venous Thromboembolism – Following the Data (BMS/Pfizer) ICC Capital Suites 14-16
-
Improving Patient Care through Innovative Thrombosis and Haemostasis Testing. LumiraDx: Microfluidic Technology in POC Testing (LumiraDx) ICC Capital Suites 1
-
Approaches to Standardisation and Monitoring for Haemophilia Gene Therapy: Consistency, Considerations and Challenges (Pfizer) ICC Capital Suites 7&12
-
Improving Outcomes in Acute Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Can We Reduce Mortality? (Sanofi) ICC Capital Suites 10&11
-
Factors to Consider: Expert Perspectives on Haemophilia A (Sobi Sanofi) ICC Capital Suites 8&9
-
A Chronic Disease Burden: Exploring the Acute and Long-term Manifestations of TTP on Patients’ Lives (Takeda Pharmaceutical Company Limited) ICC Capital Suites 2-4
Tuesday, July 12, 12:15 – 13:00 Presentation Theaters
-
Breakthrough Applications for Thrombin Generation (Diagnostica Stago) Presentation Theater 4
-
Current Advances in Deficient Factors, D-Dimer and Thrombophilia Testing (HORIBA Medical) Presentation Theater 3
-
Insights From Real World Practice to Support Haemophilia B Patients (Sobi Sanofi) Presentation Theater 1
-
Building a Future in Haemostasis: A new-age in Laboratory Workflow and Automation with the Sysmex CN-Series (Sysmex) Presentation Theater 2
Tuesday, July 12, 13:15 – 14:30 Supported Symposia
-
Strategies for Assessing and Managing DOAC-Related Bleeding (AstraZeneca) ICC Capital Suites 10&11
-
Focus on Females: Patient Experience & Novel Treatment Strategies in Bleeding Disorders (Octapharma AG) ICC Capital Suites 7&12
-
Advances in Diagnosis and Management of Bleeding Disorders (Roche) ICC Capital Suites 2-4
-
Medically-Ill Patients: VTE Prophylaxis in Hospital and Beyond (Sanofi) ICC Capital Suites 14-16
-
Towards Health Equity: Upcoming Standards in Haemophilia Management (Sanofi) ICC Capital Suite 1
-
Immune Thrombocytopenia: A Numbers Game? (Sobi) ICC Capital Suites 8&9
-
Looking Towards the Future: Individualizing Treatment for Patients with Congenital and Acquired Hemophilia A (Takeda Pharmaceutical Company Limited) ICC Capital Suite 17
For more information on these sessions, visit the online program here.